M

Mercury Clinical Research, Inc. | Houston, TX

Research site

(Unclaimed)

Location

1328 S. Loop W, Suite 200, Houston, Texas, United States of America

Site insights

Top conditions

Top treatments

Baloxavir Marboxil

Selonsertib

Tanezumab

JNJ-53718678

BMS-512148

Rilematovir

Nimenrix

GS-4997

Dapagliflozin

TC-6987

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and hu...

Active, not recruiting

Human Metapneumovirus

Respiratory Syncytial Virus

Biological: Placebo

Biological: mRNA-1345

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a...

Enrolling

COVID-19

SARS-COV-2 Infection

Biological: Placebo

Biological: BNT162b2 Vaccine

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (CORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which wil...

Active, not recruiting

RSV Immunization

Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine

Biological: Streptococcus pneumoniae vaccine

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting

COVID-19

Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

Other: Placebo